Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoarthritis and Bone Disorders

Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk

Scott Baltic  |  January 22, 2018

NEW YORK (Reuters Health)—Use of epidural steroid injections (ESIs) “should be approached with prudence,” particularly in patients who are at risk for osteoporotic fractures, such as women of postmenopausal age, according to authors of a systematic review. Although the literature presents a mixed picture, ESIs in doses as low as 80 mg methylprednisolone equivalents seem…

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Will Boggs MD  |  January 17, 2018

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

Hip Fractures Increasing in Older U.S. Women

Cheryl Platzman Weinstock  |  January 16, 2018

(Reuters Health)—The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients. Hip fracture rates declined each year from 2002–2012, the researchers found. But starting in 2013, hip fracture rates leveled off and were higher than expected….

Vitamin D, Calcium Supplements May Not Lower Fracture Risk

Lisa Rapaport  |  January 1, 2018

(Reuters Health)—Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who don’t use these supplements, a research review suggests. Researchers examined data from 33 previous trials with a total of more than 51,000 people aged 50 or older who were living in the…

Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

Michele B. Kaufman, PharmD, BCGP  |  December 19, 2017

Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…

SIRT1: A Therapeutic Target for Osteoporosis?

Lara C. Pullen, PhD  |  November 27, 2017

New research has found the sirtuin family of proteins may be a positive regulator of bone mass. In the study, pharmacological activation of SIRT1 in mice resulted in increased bone mass, suggesting the pharmacological activation of SIRT1 may protect against osteoporosis…

Bisphosphonate Drug Holiday & Hip Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  November 21, 2017

New research found women on bisphosphonate therapy who take a drug holiday experience a higher rate of hip fracture…

Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids

Reuters Staff  |  November 8, 2017

NEW YORK (Reuters Health)—Early oral bisphosphonate use is associated with a lower risk of fractures among oral-glucocorticoid users, researchers from Canada report. Bisphosphonates are commonly used for glucocorticoid-induced osteoporosis, but their efficacy has been established only in primary osteoporosis, where the mechanism of action of bone loss differs from that seen with glucocorticoid use. Dr….

Researchers Examine Lifetime Risk of Total Hip Replacements

Arthritis Care & Research  |  November 6, 2017

Total hip replacement (THR) surgery is an effective way to reduce pain and improve function in people with advanced hip osteoarthritis (OA). In light of aging populations, there’s a need to use contemporary, population-level data to plan for future service provision. In a study designed to compare THR data across countries, researchers demonstrated a significant increase in the overall use of and lifetime risk for THR from 2003 to 2013. Women consistently had a higher lifetime risk of surgery than men in all five countries studied, whereas men in all five countries demonstrated a significant increase in lifetime risk for THR over time…

Infiltrating the Disc: Mast Cells & Back Pain

Lara C. Pullen, PhD  |  November 6, 2017

Mast cells may become a therapeutic target for low back pain, according to new research. Researchers found mast cells can infiltrate intervertebral disc cells and play a role in their degeneration. Specifically, mast cells and the cytokine, IL-6, were both more likely to be found in painful intervertebral discs surgically removed from patients than in control discs…

  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences